Cargando…

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Soomin, Woo, Ji Won, Lee, Kyoungyul, Park, So Yeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pathologists and the Korean Society for Cytopathology 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986968/ https://www.ncbi.nlm.nih.gov/pubmed/31693827 http://dx.doi.org/10.4132/jptm.2019.11.03

Ejemplares similares

Centromere 17 copy number gain reflects chromosomal instability in breast cancer
por: Lee, Kyoungyul, et al.
Publicado: (2019)

Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
por: Woo, Ji Won, et al.
Publicado: (2019)

Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers
por: Woo, Ji Won, et al.
Publicado: (2020)

Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast
por: Kim, Milim, et al.
Publicado: (2020)

Clinical implications of changes in the diversity of c-MYC copy number variation after neoadjuvant chemotherapy in breast cancer
por: Chung, Yul Ri, et al.
Publicado: (2018)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
por: Chung, Yul Ri, et al.
Publicado: (2021)

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Interpretation of breast cancer screening guideline for Chinese women
por: Huang, Yubei, et al.
Publicado: (2019)

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
por: Ahn, Soomin, et al.
Publicado: (2018)

Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
por: Bergeron, Anthony, et al.
Publicado: (2023)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
por: Bae, Young Kyung, et al.
Publicado: (2012)

Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity
por: Ahn, Soomin, et al.
Publicado: (2020)

Expression of Autophagy-Related Proteins According to Androgen Receptor and HER-2 Status in Estrogen Receptor-Negative Breast Cancer
por: Kim, Ji-Ye, et al.
Publicado: (2014)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data
por: Suh, Koung Jin, et al.
Publicado: (2022)

Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast
por: Kim, Milim, et al.
Publicado: (2021)

Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
por: Ahn, Sangjeong, et al.
Publicado: (2015)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma
por: Ryu, Yoon-Jong, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Alu and LINE-1 Hypomethylation Is Associated with HER2 Enriched Subtype of Breast Cancer
por: Park, So Yeon, et al.
Publicado: (2014)

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
por: Kwak, Yoonjin, et al.
Publicado: (2017)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
por: Kim, Ji-Yeon, et al.
Publicado: (2021)

What we need to know when performing and interpreting US elastography
por: Park, So Hyun, et al.
Publicado: (2016)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vrq44lpnt4phbsiob961imdhiu